The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

Abstract Background The predictive role of blood-based tumor mutation burden (bTMB) for selecting advanced nonsmall cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs) is still under debate. Therefore, the purpose of this meta-analysis was to evaluate the eff...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: He Ba, Lei Liu, Qiang Peng, Jie Chen, Yao-dong Zhu
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
PD-1
PD-L1
NSCLC
Tumor mutation burden
Blood
Lung cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/1cf3a60e35a64ae89845b53e7c9f72fa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares